

**Dr. Firuza Patel** 

Dept of Radiotherapy & Oncology, RCC, PGIMER, Chandigarh



Dr. Ketayun Ardeshir Dinshaw.



- The basic principles of brachytherpy have not changed much during the past 100 years of radiotherapy
- Recent advances has made brachytherapy
  - Much more efficient for the patient
  - Much safer for the staff from radiation protection point of view



- Brachytherapy Definitions
  - Interstitial Brachytherapy -
    - sources are implanted in the tumor
  - Contact Brachytherapy Plesiobrachytherapy
    - Sources are close to the tumor
    - Intracavitary
    - Intraluminal
    - Endovascular
    - Surface brachytherapy



 In intracavitary application, radioactive sources are placed in the uterine cavity and vagina, usually inside a predefined applicator with special geometry.

 It is the oldest form of "conformal treatment" without heavy technological involvement & cost



- The uterine cervix is ideally suited for Intracavitary application because
  - 1. The endocervical canal and vaginal vault form a suitable vehicle to carry radioactive sources
  - 2. The normal cervical tissues and vaginal vault epithelium are relatively radioresistant and tolerate high doses of irradiation
  - 3. The intensity of irradiation rapidly falls off with distance from the intracavitary sources. This restricts the amount of irradiation received by normal tissues beyond the cervix region.



Advantages:

1. High dose in short time.

Cervix	: 20,000-25,000 cGys.
Uterus	: 20,000-30,000 cGys.
Vagina	: 10,000 – cGys.

- 2. Control rate higher.
- 3. Sharp fall of dose, less normal tissue damage.
- 4. Less late radiation morbidity.
- 5. Preservation of normal anatomy.
- 6. Better sexual functional life.



### Effect of ICBT on survival

Treatment		%age Survival at 5 years			
1.	Ext.RT alone	36%			
2.	Ext.RT+ICBT	67%			
3.	Single ICBT	<b>60%</b>			
4.	2 or more ICBT	<b>73%</b>			

 In the management of carcinoma cervix intracavitary application plays a sheet anchor role and is responsible for most of the cures.



- Radiotherapy treatment
- Proportion of Ext RT increases with tumour bulk and stage.
- Except for small tumours, Ext RT precedes ICRT.
- All treatment should be completed in 50 days
- Para-central dose should be 80-90 Gy.
- Pelvic sidewall dose should be 45-60 Gy.

### **Dose escalation**

Radiotherapy and Oncology 93 (2009) 311-315



Cervix cancer brachytherapy

Dose–effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy

Johannes C.A. Dimopoulos <sup>a</sup>,\*, Richard Pötter <sup>a</sup>, Stefan Lang <sup>a</sup>, Elena Fidarova <sup>a</sup>, Petra Georg <sup>a</sup>, Wolfgang Dörr <sup>b</sup>, Christian Kirisits <sup>a</sup>


D90 of HRCTV	Local reccurrence
<87 Gy	20%
>87Gy	4%



- Applicators
- All applications must be done under sedation



Standardised



Personaliseed



- Conditions to be met for successful ICBT
- An adequate dose has to be delivered to the paracervical areas.
- Geometry of the radioactive sources must prevent under dosed regions on and around the cervix.
- Mucosal tolerance has to be respected.
- Optimal placement "Pear-Shaped" distribution delivering a high dose to the cervix and para-cervical tissues and a reduced dose to rectum and bladder "Banana-Shaped"




- Mucosal Tolerance
- Local dose to cervix should be 2<sup>1/2</sup> 3 times the paracervical dose
- Surface dose to vaginal mucosa should be <150 Gy to proximal & < 90 Gy to distal vagina</li>
- Rectal dose should be <75 Gy
- Bladder dose should be <80 Gy



### **Lateral View of Applicator Placement**


- Tandem 1/3 of the way between S1 – S2 and the symphysis pubis
- The tandem midway between the bladder and S1 - S2
- Marker seeds should be placed in the cervix
- Ovoids should be against the · cervix (marker seeds)
- Tandem should bisect the ovoids
- The bladder and rectum should be packed away from the implant






#### **Anterior – Posterior View of Applicator Placement**

- The ovoids should fill the vaginal fornices, add caps to increase the size of the ovoids if necessary.
- The ovoids should be separated by 0.5 – 1.0 cm, admitting the flange on the tandem.
- The axis of the tandem should be central between the ovoids






- Tandem Loading
- To optimize the lateral dose to parametrium, the tandem should be as long as anatomy permits but not more than 6 cm.
- As the tandem size increases the penetration or "lateral throw-off" of the dose distribution increases
- Increase in tandem length increases the point "B" contribution relative to the uterine cavity surface dose






- Ovoid Loading
- The largest ovoids that permits adequate separation to admit the flange on the tandem between them without causing downward displacement of the ovoids should be used.
- In order to optimize the ratio between the dose at depth and the vaginal mucosal dose.
- As colpostat diameter increases from 2cm to 3cm the vaginal surface dose decreases by 35% relative to the point "A" dose.





#### **Historical Systems / Techniques**






- Manchester System
- Developed by Todd & Meredith in 1930
- Defined the treatment in terms of dose to a point.
- Defined two points A & B
- Abandoned previous dosage system of mg./hrs. in favour of roentgen unit.
- Designed a set of applicators and their loading which would give the same dose rate irrespective of the combination of applicators used




### **Definition of Point A**

Pt A was originally defined as 2cm superior to the vaginal fornix & 2cm lateral to the cervical canal



Later it was redefined to be 2cm superior to the external cervical os (or lower end of tandem) & 2 cm lateral to the cervical canal





- In the revised definition Point A is now fixed to the tandem
- Since the distance from the caudal most intrauterine source tip to the colpostat centre

   (tandem to colpostat displacement)
   varies from patient to patient the vaginal contribution to revised Pt A is highly variable
- Hence dose delivered to the tumor will be incorrect



- Loading of applicators
- In order that point A receives same dose rate, no matter which ovoid combination is used ,it is necessary to have different radium loadings for each applicator size
- Dose rate 57.5 R/hr to point A
- Not more than 1/3 dose to point A must be delivered from vaginal radium



### **Manchester Loading**

Table 4.12 Dose rates at point A for standard Manchester loadings

Applicator	Loading	Configuration	Dose rate at point A (cGy h <sup>-1</sup> )
6-cm uterine tube	6, 4, 4 units		34.4
4-cm uterine tube	6, 4 units		34.2
2-cm uterine tube	8 units		27.3
Large ovoids	9 units	1-cm spacer	18.3
Medium ovoids	8 units	1-cm spacer	18.8
Small ovoids	7 units	1-cm spacer	18.9
Large ovoids	9 units	Washer	18. <del>9</del>
Medium ovoids	8 units	Washer	19.0
Small ovoids	7 units	Washer	19.0
Large ovoids	9 units	In tandem	14.6
Medium ovoids	8 units	In tandem	14.9
Small ovoids	7 units	In tandem	14.8

The unit of source activity is 18 µGy h<sup>-1</sup> (2.5 mg radium equivalent).



### **Manchester Loading**


Table 4.12 Dose rates at point A for standard Manchester loadings


Applicator	Loading	Configuration	Dose rate at point A (cGy h <sup>-1</sup> )		
6-cm uterine tube	6, 4, 4 units		34.4		
4-cm uterine tube	6, 4 units		34.2		
2-cm uterine tube	8 units		27.3		
Large ovoids	9 units	1-cm spacer	18.3		
Medium ovoids	8 units	1-cm spacer	18.8		
Small ovoids	7 units	1-cm spacer	18.9		
Large ovoids	9 units	Washer	18. <del>9</del>		
Medium ovoids	8 units	Washer	19.0		
Small ovoids	7 units	Washer	19.0		
Large ovoids	9 units	In tandem	14.6		
Medium ovoids	8 units	In tandem	14.9		
Small ovoids	7 units	In tandem	14.8		

The unit of source activity is 18  $\mu$ Gy h<sup>-1</sup> (2.5 mg radium equivalent).



### **Tandem Loading**





1, 3, 5, 7, 9,12,15,18,21 Pt A – 700 cGy Bladder – 266 cGy Rectum – 390 cGy 3, 6, 9,12,15,18,21 Pt A – 700 cGy Bladder – 281 cGy Rectum – 416 cGy



### **Optimisation**

Analyzed parameters using 2.5 mm step positions for uterine tandem

	$T_{\rm u}/T_{\rm v}$						
	1:4	1:3	1:2	1:1 <sup>a</sup>	1:0.5	1:0.33	1:0.25
D <sub>A</sub> (%)	100	100	100	100	100	100	100
$D_{\rm R}~(\%)$	58.3	55	48.9	40.6	34.9	32.6	31.3
$D_{\rm B}~(\%)$	55	54.5	53.4	52.1	51.1	50.8	50.5
$D_{\rm B mean}$ (%)	28.4	28	26.9	25.6	24.7	24.4	24.1
h (cm)	9.1	9.1	9.0	8.8	8.7	8.6	8.6
w (cm)	6.5	6.3	6.1	5.5	5.0	4.7	4.6
<i>t</i> (cm)	4.0	3.9	4.0	3.9	3.9	4.0	4.1
hwt (cm <sup>3</sup> )	236.2	224.7	218.4	186	170.3	162.8	160.3
$T_{\rm tot}$ (s)	656.5	653.9	637.9	621.6	609.1	607	602

<sup>a</sup> In the 1:1 ( $T_u/T_v$ ) ratio, the treatment time for each step was 16.8 s when delivering 100 cGy to point A.



- Rectal dose is mainly affected by vaginal source weightings
- To lower the rectal doses the dwell times for the vaginal sources must be decreased
- Width of the reference volume will also decrease
- Hence attention must be paid to the inclusion of the tumor volume into the reference volume.




Fig. 4. Oblique coronal views of the reference dose distribution of uterine and vaginal sources with 2.5 mm steps for  $(T_u/T_v)$ : 1:1; 1:2; 1:4; 1:0.5; and 1:0.25 ratios.






Fig. 7. Oblique sagittal views of the reference dose distribution of uterine sources with 5 mm steps and vaginal sources with 2.5 mm steps for  $(T_u/T_v)$ : 1:1; 1:2; 1:4; 1:0.5; and 1:0.25 ratios.








# **Dose to Organs at risk: 2D**




### **Dose to bladder and rectum: ICRU Points**











Deshpande DD, et al. 1997;42:163-6











# Thank you